China Resources Pharmaceutical Group Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 5/6
China Resources Pharmaceutical Group hat ein Gesamteigenkapital von CN¥93.0B und eine Gesamtverschuldung von CN¥60.9B, wodurch sich der Verschuldungsgrad auf 65.5% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CN¥246.8B bzw. CN¥153.8B. China Resources Pharmaceutical Group Das EBIT des Unternehmens beträgt CN¥11.0B, so dass der Zinsdeckungsgrad 6.2 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CN¥32.2B.
Wichtige Informationen
77.1%
Verhältnis von Schulden zu Eigenkapital
CN¥74.87b
Verschuldung
| Zinsdeckungsgrad | 8.3x |
| Bargeld | CN¥33.08b |
| Eigenkapital | CN¥97.12b |
| Gesamtverbindlichkeiten | CN¥169.24b |
| Gesamtvermögen | CN¥266.36b |
Jüngste Berichte zur Finanzlage
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27Recent updates
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Aug 30China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Jun 01Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%
May 13China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697
Apr 28China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: 3320Die kurzfristigen Aktiva des Unternehmens (CN¥178.6B) übersteigen seine kurzfristigen Passiva (CN¥134.2B).
Langfristige Verbindlichkeiten: 3320Die kurzfristigen Vermögenswerte des Unternehmens (CN¥178.6B) übersteigen seine langfristigen Verbindlichkeiten (CN¥19.6B).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: 3320Die Nettoverschuldung im Verhältnis zum Eigenkapital (43%) wird als hoch angesehen.
Schulden abbauen: 3320 Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 89.2% auf 65.5% zurückgegangen.
Schuldendeckung: 3320Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (25.6%).
Zinsdeckung: Die Zinszahlungen für die Schulden von 3320 sind durch das EBIT gut gedeckt (6.2x coverage).